Johnson & Johnson (JNJ) Price & Analysis

Compare

149 Followers

JNJ Stock Chart & Stats

€205.60

-€0.18(-0.13%)

At close: Jan 09 4:00 PM EST

€205.60

-€0.18(-0.13%)

Day’s Range― - ―

52-Week Range€128.16 - €209.00

Previous CloseN/A

Volume223.00

Average Volume (3M)3.83K

Market Cap

€502.13B

Enterprise Value€612.60B

Total Cash (Recent Filing)€20.10B

Total Debt (Recent Filing)€47.93B

Price to Earnings (P/E)21.1

Beta0.20

Next Earnings

Apr 14, 2026

EPS Estimate

2.26

Next Dividend Ex-DateN/A

Dividend Yield2.54%

Share Statistics

EPS (TTM)2.07

Shares Outstanding2,409,899,000

10 Day Avg. Volume3,073

30 Day Avg. Volume3,825

Financial Highlights & Ratios

PEG Ratio0.21

Price to Book (P/B)6.18

Price to Sales (P/S)5.35

P/FCF Ratio25.59

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€205.18

Price Target Upside-0.20% Downside

Rating ConsensusModerate Buy

Number of Analyst Covering13

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Analyst Upgrades And Earnings OutlookAnalyst upgrades based on higher revenue and earnings estimates from new products signal potential upside to consensus estimates and support a more favorable valuation stance.

Product Pipeline & LaunchesSeveral late-stage and newly launched medicines such as Tremfya and Inlexzo are positioned to be meaningful revenue drivers if market uptake and reimbursement proceed as expected.

Strategic Portfolio RestructuringSeparation of the orthopaedics business is designed to sharpen focus on core growth areas and could improve capital allocation and management's ability to drive targeted expansion.

Bears Say

Litigation RiskOngoing talc litigation remains an unresolved risk that could lead to material liabilities and sustained investor uncertainty.

Safety Profile And Adoption RiskElevated infection rates and early infection-related deaths observed with Tecvayli plus Darzalex before additional prophylactic measures could slow adoption and invite regulatory scrutiny.

Valuation ConstraintsLimited room for further valuation multiple expansion could cap upside and leave total returns dependent on operational execution alone.

Johnson & Johnson News

Johnson & Johnson announces new long-term data from Quasar LTE study

Johnson & Johnson announced new long-term data from the Quasar long-term extension, LTE, study showing that Tremfya sustained...

3h ago

JNJ

The Week That Was, The Week Ahead: Macro and Markets, Feb. 22

U.S. stocks ended the week higher, even as sharp moves in individual names kept traders on edge. The...

13h ago

Johnson & Johnson (JNJ) Gears Up for a Potential $20B Sale of Orthopedics Unit

Healthcare giant Johnson & Johnson ($JNJ) is gearing up to sell its orthopedics unit, with several large buyout...

3d ago

JNJ

Johnson & Johnson says Rybrevant Faspro shows strong clinical benefit

Johnson & Johnson “announced new results from the Phase 1b/2 OrigAMI-4 study showing that first-line treatment with investigational...

3d ago

JNJ

J&J weighs sale of DePuy amid private equity interest, Bloomberg says

Johnson & Johnson is preparing a potential sale of its orthopedics unit DePuy Synthes, Michelle Davis, Vinicy Chan,...

3d ago

JNJ

Johnson & Johnson preparing for sale of orthopedics unit, Bloomberg says

14:16 EST Johnson & Johnson preparing for sale of orthopedics unit, Bloomberg says Published first on TheFly –...

3d ago

JNJ

FDA to begin requiring on clinical trial

The New England Journal of Medicine reports: “Sounding Board announces a new FDA policy that the default requirement...

4d ago

AZN

BMY

FDA to begin requiring one clinical trial in drug approvals

The New England Journal of Medicine reports: “Sounding Board announces a new FDA policy that the default requirement...

4d ago

AZN

BMY

Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!

Traders looking for the latest stock market stories will find them in the TipRanks daily wrap-up. ...

4d ago

AMD

GIS

Johnson & Johnson Stock (JNJ) Rises on $1B Pennsylvania Plant to Expand U.S. Manufacturing

Johnson & Johnson’s ($JNJ) shares rose fractionally on Wednesday morning after the American pharma giant rolled out plans...

4d ago

AZN

JNJ

J&J announces $1B investment in next generation cell therapy facility in PA

Johnson & Johnson announced a more than $1B investment in a next generation cell therapy manufacturing facility in...

4d ago

JNJ

Johnson & Johnson granted BTD for RYBREVANT FASPRO from FDA

Johnson & Johnson announced that the FDA has granted Breakthrough Therapy Designation, or BTD, for subcutaneous amivantamab and...

4d ago

JNJ

Genmab sees 2026 revenue $4.065B-$4.395B, consensus $4.13B

Genmab (GMAB) expects its 2026 revenue to be in the range of $4.1B-$4.4B, compared to $3.7B in 2025....

5d ago

JNJ

GMAB

Johnson & Johnson’s Rybrevant Faspro regimen approved by FDA for NSCLC

Johnson & Johnson announced the FDA has approved a new, simplified monthly dosing schedule for Rybrevant Faspro –...

5d ago

JNJ

JNJ FAQ

What was Johnson & Johnson’s price range in the past 12 months?

Johnson & Johnson lowest stock price was €128.16 and its highest was €209.00 in the past 12 months.

What is Johnson & Johnson’s market cap?

Johnson & Johnson’s market cap is €502.13B.

When is Johnson & Johnson’s upcoming earnings report date?

Johnson & Johnson’s upcoming earnings report date is Apr 14, 2026 which is in 51 days.

How were Johnson & Johnson’s earnings last quarter?

Johnson & Johnson released its earnings results on Jan 21, 2026. The company reported €2.072 earnings per share for the quarter, missing the consensus estimate of €2.075 by -€0.003.

Is Johnson & Johnson overvalued?

According to Wall Street analysts Johnson & Johnson’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Johnson & Johnson pay dividends?

Johnson & Johnson pays a Quarterly dividend of €1.124 which represents an annual dividend yield of 2.54%. See more information on Johnson & Johnson dividends here

What is Johnson & Johnson’s EPS estimate?

Johnson & Johnson’s EPS estimate is 2.26.

How many shares outstanding does Johnson & Johnson have?

Johnson & Johnson has 2,409,899,000 shares outstanding.

What happened to Johnson & Johnson’s price movement after its last earnings report?

Johnson & Johnson reported an EPS of €2.072 in its last earnings report, missing expectations of €2.075. Following the earnings report the stock price went down -1.197%.

Which hedge fund is a major shareholder of Johnson & Johnson?

Currently, no hedge funds are holding shares in DE:JNJ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Johnson & Johnson Stock Smart Score

Neutral

Fundamentals

Return on Equity

35.03%

Trailing 12-Months

Asset Growth

10.61%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Johnson & Johnson (JNJ) Earnings & Revenues

Historic Earnings Reports

JNJ Company Deck

JNJ Earnings Call

Q4 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call highlights a dominant message of accelerating, portfolio-driven growth: robust revenue and adjusted EPS growth, strong free cash flow, numerous approvals and late-stage programs, and notable commercial momentum across oncology, immunology, neuroscience, and MedTech. Management provided constructive 2026 guidance, reiterated long-term ambition (double-digit growth by the end of the decade), and outlined capital deployment and the orthopedics separation. Offsetting risks include material STELARA biosimilar erosion (a substantial multi-hundred-basis-point headwind), elevated litigation and one-time charges, tariff pressures, competitive dynamics in select MedTech areas, and modest share-count dilution. On balance, the positives — broad-based commercial strength, pipeline and approval milestones, robust cash generation, and clear guidance — materially outweigh the near-term headwinds.View all DE:JNJ earnings summaries

JNJ Sales Breakdown

64.12% Innovative Medicine

35.88% MedTech

JNJ Stock 12 Month Forecast

Average Price Target

€205.18

▼(-0.20% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"130":"€130","177":"€177","224":"€224","153.5":"€153.5","200.5":"€200.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":223.75539205,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€223.76</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":205.17947271,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€205.18</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":183.22611349,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€183.23</span>\n  </div></div>","useHTML":true}}],"tickPositions":[130,153.5,177,200.5,224],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,194.02,196.30733785,198.5946757,200.88201355,203.1693514,205.45668925,207.7440271,210.03136495,212.3187028,214.60604065,216.8933785,219.18071635,221.4680542,{"y":223.75539205,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,194.02,194.87842097769231,195.73684195538462,196.59526293307692,197.45368391076923,198.31210488846153,199.17052586615384,200.02894684384617,200.88736782153848,201.74578879923078,202.60420977692308,203.4626307546154,204.3210517323077,{"y":205.17947271,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,194.02,193.18970103769232,192.35940207538462,191.52910311307693,190.69880415076923,189.86850518846154,189.03820622615385,188.20790726384615,187.37760830153846,186.54730933923076,185.71701037692307,184.88671141461538,184.05641245230768,{"y":183.22611349,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":141.997,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":153.678,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":143.017,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":134.468,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.873,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.511,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":141.652,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":150.185,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":156.227,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":162.288,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":177.64,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":176.7,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":194.02,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >